Akebia Therapeutics (AKBA) Profit After Tax (2016 - 2025)
Historic Profit After Tax for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $540000.0.
- Akebia Therapeutics' Profit After Tax rose 10269.47% to $540000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.9 million, marking a year-over-year increase of 6541.79%. This contributed to the annual value of -$69.4 million for FY2024, which is 3367.36% down from last year.
- According to the latest figures from Q3 2025, Akebia Therapeutics' Profit After Tax is $540000.0, which was up 10269.47% from $247000.0 recorded in Q2 2025.
- Over the past 5 years, Akebia Therapeutics' Profit After Tax peaked at $29.4 million during Q2 2022, and registered a low of -$83.0 million during Q2 2021.
- Moreover, its 5-year median value for Profit After Tax was -$18.0 million (2024), whereas its average is -$25.8 million.
- As far as peak fluctuations go, Akebia Therapeutics' Profit After Tax surged by 13546.45% in 2022, and later plummeted by 381400.65% in 2024.
- Akebia Therapeutics' Profit After Tax (Quarter) stood at -$69.9 million in 2021, then soared by 91.31% to -$6.1 million in 2022, then surged by 110.11% to $614000.0 in 2023, then crashed by 3814.01% to -$22.8 million in 2024, then skyrocketed by 102.37% to $540000.0 in 2025.
- Its Profit After Tax stands at $540000.0 for Q3 2025, versus $247000.0 for Q2 2025 and $6.1 million for Q1 2025.